{{Drugbox 
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408581688
| IUPAC_name = 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
| image = Loxapine.svg
| width = 200px
| image2 = Loxapine ball-and-stick model.png
| width2 = 200px

<!--Clinical data-->
| tradename = Several trade names worldwide<ref name=genericnames>Drugs.com [http://www.drugs.com/international/loxapine.html International names for loxapine] Page accessed March 3, 2016</ref>
| Drugs.com = {{drugs.com|monograph|loxapine-succinate}}
| MedlinePlus = a682311
| DailyMedID = 50e11732-7387-452d-b3e6-db3a431d5c4a
| licence_EU = Adasuve
| licence_US = Loxapine
| pregnancy_US = C
| legal_US = Rx-only
| legal_AU = S4
| routes_of_administration = Oral, powder for inhalation

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 96.8%<ref name = "DrugPoint" />
| metabolism = Extensive [[Liver|hepatic]]; active metabolites include [[amoxapine]] and 8-hydroxyloxapine. Inhibits [[P-glycoprotein|P-gp]] and is a substrate of [[CYP1A2]], [[CYP3A4]] and [[CYP2D6]]<re name = "DrugPoint" />
| elimination_half-life = 4 hours (oral); 7.61 hours (inhalation) <ref name = "DrugPoint" />
| excretion = Majority are excreted within 24 hours, main route through urine (conjugated metabolites), small amounts through the feces (unconjugated metabolites)

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1977-10-2
| ATC_prefix = N05
| ATC_suffix = AH01
| ATC_supplemental = 
| PubChem = 3964
| IUPHAR_ligand = 205
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00408
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3827
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LER583670J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02340
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 50841
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 831

<!--Chemical data-->
| C=18 | H=18 | Cl=1 | N=3 | O=1
| molecular_weight = 327.808 g/mol
| SMILES = Clc2ccc1Oc4c(/N=C(\c1c2)N3CCN(C)CC3)cccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XJGVXQDUIWGIRW-UHFFFAOYSA-N
| melting_point = 109
| melting_high = 110
}}

'''Loxapine''' (several trade names worldwide<ref name=genericnames/>) is a [[typical antipsychotic]] [[medication]], used primarily in the treatment of [[schizophrenia]].  The drug is a member of the  [[dibenzoxazepine]] class and structurally related to [[clozapine]] (which belongs to the chemically akin class of [[dibenzodiazepine]]s). Several researchers have argued that loxapine may behave as an [[atypical antipsychotic]].<ref name=pmid10340686>{{cite journal |author=Glazer WM |title=Does loxapine have "atypical" properties? Clinical evidence |journal=The Journal of Clinical Psychiatry |volume=60 |issue=Suppl 10 |pages=42–6 |year=1999 |pmid=10340686}}</ref>

Loxapine may be metabolized by ''N''-demethylation to [[amoxapine]], a [[tetracyclic antidepressant]].<ref name=pmid1860915>{{cite journal |vauthors=Cheung SW, Tang SW, Remington G |title=Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography |journal=Journal of Chromatography |volume=564 |issue=1 |pages=213–21 |date=March 1991 |pmid=1860915 |doi=10.1016/0378-4347(91)80083-O}}</ref>

==Medical uses==
The typical starting dosage is 10&nbsp;mg twice daily; usual dose range 30–50&nbsp;mg twice daily; maximum recommended dosage is 250&nbsp;mg per day. The [[US Food and Drug Administration]] (FDA) has approved loxapine inhalation powder 10&nbsp;mg (Adasuve, Alexza Pharmaceuticals) for the acute treatment of agitation associated with schizophrenia or [[bipolar I disorder]] in adults.<ref>Harrison, Pam: Inhalant Approved for Agitation in Bipolar I, Schizophrenia. Medscape. Dec 24, 2012.</ref>

A brief review of loxapine<ref name="pmid1747161">{{cite journal |title=Clozapine and loxapine for schizophrenia |journal=Drug and Therapeutics Bulletin |volume=29 |issue=11 |pages=41–2 |date=May 1991 |pmid=1747161}}</ref> found no conclusive evidence that it was particularly effective in patients with [[paranoid schizophrenia]]. A subsequent systematic review considered that the limited evidence did not indicate a clear difference in its effects from other antipsychotics.<ref name="pmid17943763">{{cite journal  |vauthors=Chakrabarti A, Bagnall A, Chue P, etal |title=Loxapine for schizophrenia |journal=Cochrane Database of Systematic Reviews |volume= |issue=4 |pages=CD001943 |year=2007 |pmid=17943763 |doi=10.1002/14651858.CD001943.pub2 |editor1-last=Chakrabarti |editor1-first=Abhijit}}</ref>

==Precautions==
This drug is unrelated to the habit-forming [[benzodiazepine]]s, and misuse is rare.<ref name="pmid6694719">{{cite journal |doi=10.1056/NEJM198403013100920 |vauthors=Sperry L, Hudson B, Chan CH |title=Loxapine abuse |journal=The New England Journal of Medicine |volume=310 |issue=9 |pages=598 |date=March 1984 |pmid=6694719}}</ref> The risks and side effect profile are comparable to other [[antipsychotic]]s.

==Side effects==
{{further|Typical antipsychotic}}

''Note: Percentages given after possible adverse effects refer to the incidence of said adverse effects, according to DrugPoint.''<ref name = "DrugPoint" />

;Common side effects of loxapine (≥1% incidence) when inhaled include:<ref name = "DrugPoint">Truven Health Analytics, Inc. DrugPoint® System (Internet) [cited 2013 Sep 21]. Greenwood Village, CO: Thomsen Healthcare; 2013.</ref>
* Taste sense altered (14%)
* Sedated (12%)
* Pharyngitis (3%)
;Common side effects of orally-administered loxapine include:<ref name = "DrugPoint" />
* Constipation
* Dry mouth
* Akathisia
* Dizziness
*Intense Sleeping (Highest Percentage)
*Blurred Speech
* Extrapyramidal disease (dose-dependent. At lower dosages its propensity for causing extrapyramidal side effects appears to be similar to that of atypical antipsychotics<ref name = "Nordstrom">Nordstrom K. Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: an update. Neuropsychiatry [Internet]. 2012 Jun [cited 2013 Sep 21];2(3):253–60. Available from: http://www.futuremedicine.com/doi/abs/10.2217/npy.12.23</ref>
* Blurred vision
* [[Urinary retention]]
* [[Somnolence]] (which appears to be moderate in severity compared to other antipsychotic drugs<ref name = "Maudlsey">Taylor D, Paton C, Kapur S, Taylor D, South London and Maudsley NHS Trust. The Maudsley prescribing guidelines in psychiatry [Internet]. Chichester, West Sussex: John Wiley & Sons; 2012 [cited 2013 Sep 21]. Available from: http://site.ebrary.com/lib/uqat/Doc?id=10531429</ref>)
* Dyspnoea
* Nasal congestion

;Rare side effects include:<ref name = "DrugPoint" />
* Paralytic [[ileus]]
* [[Agranulocytosis]]
* [[Leukopenia]]
* [[Thrombocytopenia]]
* Hepatocellular liver damage
* [[Neuroleptic malignant syndrome]]
* Seizure
* [[Tardive dyskinesia]]
* [[Stroke]]
* [[Transient ischaemic attack]]
* Death

==Pharmacology==
{| class="wikitable floatright" style="font-size:small;"
|+ Loxapine (and metabolite)<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health || format = HTML | accessdate = 14 August 2017 | url = https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=loxapine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref><ref name="pmid22033803">{{cite journal | vauthors = Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R | title = Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 385 | issue = 2 | pages = 145–70 | year = 2012 | pmid = 22033803 | doi = 10.1007/s00210-011-0704-0 | url = }}</ref>
|-
! Site !! {{abbr|LOX|Loxapine}} !! {{abbrlink|AMX|Amoxapine}}
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 2,460 || {{abbr|ND|No data}}
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || 388 || {{abbr|ND|No data}}
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || 3,470 || {{abbr|ND|No data}}
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || 1,400 || {{abbr|ND|No data}}
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 6.6 || 0.5
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 13 || 2 (rat)
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 190 || {{abbr|ND|No data}}
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || 780 || {{abbr|ND|No data}}
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 31 || 50
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 88 || 40 (rat)
|-
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 31 || {{abbr|ND|No data}}
|-
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || 53 || {{abbr|ND|No data}}
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 151 || {{abbr|ND|No data}}
|-
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 108 || {{abbr|ND|No data}}
|-
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 80 || {{abbr|ND|No data}}
|- 
| [[Beta-1 adrenergic receptor|β<sub>1</sub>]] || >10,000 || {{abbr|ND|No data}}
|-
| [[Beta-2 adrenergic receptor|β<sub>2</sub>]] || >10,000 || {{abbr|ND|No data}}
|-
| [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] || 120 || {{abbr|ND|No data}}
|-
| [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] || 445 || {{abbr|ND|No data}}
|-
| [[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]] || 211 || {{abbr|ND|No data}}
|-
| [[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]] || 1,270 || {{abbr|ND|No data}}
|-
| [[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]] || 166 || {{abbr|ND|No data}}
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 54 || {{abbr|ND|No data}}
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 11 || 21
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 19 || 21
|-
| [[Dopamine D4 receptor|D<sub>4</sub>]] || 8.4 || 21
|-
| [[Dopamine D5 receptor|D<sub>5</sub>]] || 75 || {{abbr|ND|No data}}
|-
| [[Histamine H1 receptor|H<sub>1</sub>]] || 2.2–4.9 || 7.9–25
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || 208 || {{abbr|ND|No data}}
|-
| [[Histamine H3 receptor|H<sub>3</sub>]] || 55,000 || >100,000
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || 5,050–8,710 || 6,310
|-
| {{abbrlink|SERT|Serotonin transporter}} || >10,000 || 58
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 5,700 || 16
|-
| {{abbrlink|DAT|Dopamine transporter}} || >10,000 || 58
|- class="sortbottom"
| colspan="3" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

The data in the table to the right was obtained from the PDSP Ki database and they are for binding towards human cloned proteins (receptor and transporter) unless otherwise specified.<ref name="PDSP" />

==See also==
* [[Amoxapine]]
* [[Clotiapine]]

==References==
{{Reflist|30em}}

==External links==
* [http://www.medscape.com/druginfo/monograph?cid=med&drugid=14375&drugname=Loxapine+Succinate+Oral&monotype=monograph&secid=3 Product monograph] from Medscape (free registration required).

{{Antipsychotics}}
{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Chloroarenes]]
[[Category:Dibenzoxazepines]]
[[Category:Piperazines]]
[[Category:Typical antipsychotics]]